Fluoropyrimidine-Associated Cardiotoxicity: A Retrospective Case-Control Study. Academic Article uri icon

Overview

abstract

  • BACKGROUND: The fluoropyrimidines, 5-fluorouracil (5-FU) and capecitabine, are commonly used chemotherapeutic agents that have been associated with coronary vasospasm. METHODS: In this retrospective case-control study, we identified patients at our institution who received 5-FU or capecitabine in 2018. We compared characteristics of patients who experienced cardiotoxicity with controls. We described phenotypes and outcomes of cardiotoxic cases. RESULTS: We identified 177 patients who received fluoropyrimidines. After adjudication, 4.5% of the cohort met the criteria for cardiovascular toxicity. Coronary artery disease was more common among cases than controls (38% vs. 7%, p < .05). There was also a trend toward increased prevalence of cardiovascular risk factors in cases compared with controls. Most cardiotoxic cases had chest pain, although a minority of cases presented with nonischemic cardiomyopathy. CONCLUSION: Cardiotoxicity phenotypes associated with fluoropyrimidine use are not limited to coronary vasospasm. Cardiac risk factors and ischemic heart disease were highly prevalent among patients with cardiotoxicity.

publication date

  • December 16, 2019

Research

keywords

  • Cardiotoxicity
  • Fluorouracil

Identity

PubMed Central ID

  • PMC7066698

Scopus Document Identifier

  • 85077044412

Digital Object Identifier (DOI)

  • 10.1634/theoncologist.2019-0762

PubMed ID

  • 32162823

Additional Document Info

volume

  • 25

issue

  • 3